# SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Study · id `cardio:ct-nct05198674` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05198674](<https://clinicaltrials.gov/study/NCT05198674>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05198674

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1899 participants.

## Technical summary

Registry record NCT05198674. Allocation not applicable; no masking; primary purpose treatment. Start 2021-10-20 (actual); primary completion 2026-03-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1899 participants (enrolled count; ClinicalTrials.gov record NCT05198674, source copy `cardio:ctgov-nct05198674-2026-10-16`, retrieved 2026-11-18)
- Started: 2021-10-20 (actual) (ClinicalTrials.gov record NCT05198674, source copy `cardio:ctgov-nct05198674-2026-10-16`, retrieved 2026-11-18)
- Primary completion: 2026-03-05 (actual) (ClinicalTrials.gov record NCT05198674, source copy `cardio:ctgov-nct05198674-2026-10-16`, retrieved 2026-11-18)
- Completion: 2029-11-30 (anticipated) (ClinicalTrials.gov record NCT05198674, source copy `cardio:ctgov-nct05198674-2026-10-16`, retrieved 2026-11-18)
- Countries: United States; Australia; Belgium; France; Germany; Greece; Ireland; Monaco; Netherlands; Sweden; United Kingdom (ClinicalTrials.gov record NCT05198674, source copy `cardio:ctgov-nct05198674-2026-10-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05198674-2026-10-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
- Condition: Hypertension
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Condition: Chronic Kidney Diseases
- Condition: Diabetes Mellitus
- Intervention (Device): Renal Denervation (Symplicity Spyral™)
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

## Provenance

Content hash: e4da58c25b06d17ca20c9077810124d782678a9788c7be94189747138c910cc8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
